Affimed Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Shawn Leland

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	7.3yrs
Durata media del Consiglio di amministrazione	9.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Affimed Follow Up: Upcoming Acimtamig And AFM24 Updates Could Be Positive Catalysts

Sep 04

Affimed: AFM24's Update Was Good, Acimtamig's Should Be Better

Jun 11

The Affimed N.V. (NASDAQ:AFMD) Analysts Have Been Trimming Their Sales Forecasts

Aug 15

Need To Know: Analysts Just Made A Substantial Cut To Their Affimed N.V. (NASDAQ:AFMD) Estimates

Apr 20

AMMINISTRATORE DELEGATO

Shawn Leland (40 yo)

less than a year

Mandato

Dr. Shawn M. Leland, Pharm.D. R.Ph. serves as Chief Executive Officer at Afirmed N.V. from September, 2024. He was Interim Chief Executive Officer and Director of Fore Biotherapeutics Inc. since September...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Wolfgang Fischer	MD, COO & Member of Management Board	7.3yrs	€1.26m	0.89% $ 187.7k
Denise Mueller	Chief Business Officer & Member of Management Board	3.5yrs	€1.17m	0.55% $ 115.9k
Andreas Harstrick	Chief Medical Officer & Member of Management Board	no data	€1.14m	0.46% $ 98.1k
Shawn Leland	Chief Executive Officer	less than a year	Nessun dato	Nessun dato
Melvyn Little	Founder & Consultant	24.9yrs	Nessun dato	Nessun dato
Michael Wolf	Head of Finance & Administration	9.9yrs	Nessun dato	Nessun dato
Alexander Fudukidis	Head of Investor Relations & Director of Investor Relations	no data	Nessun dato	Nessun dato
Mary Sandin	Vice President of Marketing & Communications	no data	Nessun dato	Nessun dato

7.3yrs

Durata media

57yo

Età media

Gestione esperta: Il team dirigenziale di AFMD è esperto e expertise (durata media dell'incarico 7.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Miroslav Ravic	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Thomas Hecht	Independent Chairman of Supervisory Board	17.9yrs	€162.00k	0.24% $ 49.7k
Owen O'Connor	Member of Scientific Advisory Board	9.5yrs	Nessun dato	Nessun dato
Susanne Becker	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Andreas Engert	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Max Topp	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Christian Hucke	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Anton Hagenbeek	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Franck Morschhauser	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Ulrike Köhl	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Stephen Ansell	Member of Scientific Advisory Board	9.5yrs	Nessun dato	Nessun dato
Andrew Evens	Member of Scientific Advisory Board	8.9yrs	Nessun dato	Nessun dato

9.5yrs

Durata media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di AFMD sono considerati esperti (durata media dell'incarico 9.5 anni).

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2024/12/29 18:27
Prezzo dell'azione a fine giornata	2024/12/27 00:00
Guadagni	2024/09/30
Guadagni annuali	2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

^* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .

Fonti analitiche

Affimed N.V. è coperta da 13 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
James Birchenough	BMO Capital Markets Equity Research
Li Wang Watsek	Cantor Fitzgerald & Co.
Bradley Canino	Credit Suisse

Affimed Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Affimed N.V. Announces Chief Executive Officer Changes

Affimed N.V., Annual General Meeting, Jun 26, 2024

Affimed N.V. Announces CEO Changes

Affimed N.V. Announces Executive Changes

Affimed Announces Addition of Constanze Ulmer-Eilfort to Its Supervisory Board

Affimed N.V., Annual General Meeting, Jun 21, 2023

Recent updates

Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)

Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients

Affimed N.V. to Report Q3, 2024 Results on Nov 14, 2024

Affimed N.V. Announces Acceptance of Three Abstracts At the 2024 Ash Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma

Affimed Follow Up: Upcoming Acimtamig And AFM24 Updates Could Be Positive Catalysts

Affimed N.V. Announces Chief Executive Officer Changes

Affimed N.V. to Report Q2, 2024 Results on Sep 05, 2024

Affimed: AFM24's Update Was Good, Acimtamig's Should Be Better

Affimed N.V. to Report Q1, 2024 Results on Jun 12, 2024

Affimed N.V., Annual General Meeting, Jun 26, 2024

Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024

Affimed N.V. to Report Fiscal Year 2023 Results on Mar 28, 2024

Affimed N.V. Provides Clinical Response Update on AFM24-102 Trial in EGFR-Wildtype Non-Small Cell Lung Cancer

Affimed N.V. Announces CEO Changes

Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic Nk in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (Bv) and Checkpoint Inhibitors (Cpis)

Affimed N.V. Announces Executive Changes

Affimed N.V. to Report Q3, 2023 Results on Nov 14, 2023

Affimed N.V. Presents Preclinical Data Showing That Addition of an Innate Cell Engager to Nk and Car-Nk Cells

Affimed N.V. Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting

Affimed Announces Listing Transfer to Nasdaq Capital Markets

Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK(R) for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma

Affimed N.V. Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability

The Affimed N.V. (NASDAQ:AFMD) Analysts Have Been Trimming Their Sales Forecasts

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 14%

Affimed N.V. to Report Q2, 2023 Results on Aug 10, 2023

Affimed N.V.(NasdaqGM:AFMD) dropped from Russell 2000 Dynamic Index

New minor risk - Market cap size

Affimed Announces Addition of Constanze Ulmer-Eilfort to Its Supervisory Board

Consensus revenue estimates decrease by 22%

Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Affimed N.V., Annual General Meeting, Jun 21, 2023

Affimed N.V. to Report Q1, 2023 Results on May 23, 2023

Affimed N.V. Announces Abstracts at Annual Meeting of European Hematology Association

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Affimed N.V. Provides Regulatory Update for AFM13

Affimed N.V. Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia

Affimed N.V. Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells

Consensus revenue estimates increase by 28%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Affimed N.V. to Report Q3, 2022 Results on Nov 15, 2022

Affimed N.V. Announces Presentation of Phase 1/2 Data from Afm13 in Combination with Allogeneic NK Cells and Preclinical Afm28 Data At Ash 2022 Annual Meeting

Affimed downgraded to hold at Stifel as pipeline lacks development clarity

Health Check: How Prudently Does Affimed (NASDAQ:AFMD) Use Debt?

Now 26% undervalued after recent price drop

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Affimed Q2 2022 Earnings Preview

Affimed N.V. to Report Q2, 2022 Results on Aug 11, 2022

Affimed N.V. Establishes Scientific Advisory Board

Affimed: Preparing For Key Inflection Points

Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?

Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Affimed N.V. Announces Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies At the Annual Meeting of the American Society of Clinical Oncology

Affimed N.V. to Report Q1, 2022 Results on Jun 01, 2022

Affimed N.V. Presents Data on Innate Cell Engagers Afm24 and Afm28 at 19th Meeting of the Society for Natural Immunity

Affimed N.V. Announces Data from the Dose Escalation Phase of the Phase 1/2A Study with the company’s Innate Cell Engager

Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting

Affimed N.V. Presents Findings from the Dose-Escalation Phase of the First-In-Human Study of AFM24 in Patients with EGFR-Positive Solid Tumors

Affimed Stock: 3 Points For The Bulls

Consensus revenue estimates fall by 23%

Affimed N.V. (NASDAQ:AFMD) Analysts Just Cut Their EPS Forecasts Substantially

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Affimed N.V. Announces Publication of Preclinical Data Demonstrating Cytotoxic Potency and Efficacy of NK Cells Precomplexed with Innate Cell Engagers After Freezing & Thawing

Affimed N.V. Announces Completion of Enrollment in Redirect, the Registration-Directed Study of Afm13 in PTCL